Salvo Health, a digital GI care startup, secures $5M in Seed Prime funding led by City Light Capital and Human Ventures. Existing investors, including Torch Capital and Threshold Ventures, also participated. The NYC-based company offers hybrid “wraparound care” for chronic GI conditions, matching users with a dedicated care team. The funds will expand services to providers and scale operations.
Salvo Health, a digital gastrointestinal care startup, has successfully secured $5 million in funding in its Seed Prime round, led by City Light Capital and Human Ventures. Notable participation came from existing investors such as Torch Capital, Threshold Ventures, and Felicis Ventures, alongside angel investors including Anmol Madan, founder of Ginger Health, and Teladoc’s former chief data scientist.
In conjunction with this funding round, Emily Melton from Threshold, Rachel Parlier from City Light, and Salvo’s founder and CEO, Jeffrey Glueck, will be joining Salvo’s board of directors.
Salvo Health, headquartered in New York, specializes in providing virtual clinic services tailored for individuals dealing with chronic gastrointestinal and metabolic liver issues, such as celiac disease, fatty liver disease, irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), small intestinal bacterial overgrowth (SIBO), and dyspepsia.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The company offers a unique hybrid approach termed “wraparound care,” enabling patients to continue receiving care from their local physicians while accessing support through Salvo’s app. Users are paired with a dedicated care team comprising registered dietitians, behavioral health specialists, and licensed nurses, with the added benefit of insurance-covered interdisciplinary care.
With the newly acquired funds, Salvo aims to expand its wraparound GI services to a broader spectrum of providers, including accountable care organizations, gastroenterology private practices, and health systems.
Rachel Parlier of City Light Capital expressed enthusiasm for leading this investment, emphasizing Salvo’s potential to revolutionize healthcare delivery for individuals with GI and metabolic chronic conditions. Parlier highlighted Salvo’s role in bridging gaps in care for underserved patient populations, particularly in providing comprehensive follow-on care between appointments and post-procedures.
Since its launch in 2022 with initial funding of $10.5 million, Salvo Health has been on a trajectory to scale its virtual clinic dedicated to chronic GI conditions. Noteworthy competitors in the virtual digestive care domain include Vivante Health, which secured $31 million in funding in September, and Oshi Health, which garnered $30 million in Series B funding in April.
